查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861845

依给药途径、销售管道、品牌类型、剂型、最终用户、通路和药物类别分類的消化性溃疡药物市场－2025-2032年全球预测

Peptic Ulcer Drugs Market by Route Of Administration, Sales Channel, Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，消化性溃疡治疗市场将成长至 72 亿美元，复合年增长率为 5.38%。

关键市场统计数据
基准年 2024 47.3亿美元
预计年份：2025年 49.9亿美元
预测年份 2032 72亿美元
复合年增长率 (%) 5.38%

简要概述当前影响消化性溃疡治疗格局和相关人员决策的临床、商业性和供应方面趋势。

消化性溃疡药物治疗仍然是胃肠病学实践的基石，其临床重点在于控制症状、促进黏膜癒合和预防併发症。抑酸药物的进步和临床流程的改进重塑了消化性溃疡的诊断和治疗，使许多治疗决策从住院治疗转移到门诊和居家照护护理。患者和医护人员现在对幽门螺旋桿菌的作用、长期持续抑酸治疗的影响以及在慢性治疗中平衡疗效和安全性的必要性有了更深入的了解。

临床上，质子帮浦阻断剂已成为实现强效且持久抑酸的主要治疗方法，而H2受体拮抗剂在特定情况下或作为短期治疗仍发挥辅助作用。治疗格局受到监管措施、产品召回以及不断变化的非处方药（OTC）获取模式的影响，这些因素共同影响处方医生的行为和患者的自我管理。同时，从原料药生产到成品药製造、分销和临床应用，药品供应链正变得日益复杂，受到全球采购、监管协调和不断变化的医保报销制度的影响。

本执行摘要总结了影响消化性溃疡治疗领域的当前趋势，重点阐述了临床证据、监管动态、商业化管道和营运实际情况之间的相互作用。其目标是为决策者提供清晰、可操作的观点，将治疗效果考量与商业性和供应方面的实际情况相结合，从而支持产品系列、分销网络和相关人员参与计划等方面的明智战略发展。

科学进步、监管力度加大以及通路创新如何推动消化性溃疡药物治疗路径的策略性重塑

消化性溃疡药物的治疗和商业性格局正经历着一场变革，其驱动力包括科学进步、监管调整以及患者用药途径的转变。在科学方面，对胃酸生理和黏膜保护机制的深入了解，正在改善何时以及如何进行积极的抑酸治疗，从而推动指南的修订和处方实践的优化。同时，真实世界安全性数据和药物警戒资讯促使人们更加关注长期治疗，从而催生出更为谨慎的剂量递减方案和以合理疗程和监测为优先的共同决策工具。

监管和品质方面的挑战也在推动变革。生产诚信、原料药采购惯例以及污染事件等问题促使监管力道加大，供应商透明度也受到重视。这些压力正在加速推动产业采用更完善的品质保证措施和双重筹资策略，以保障供应的连续性。在商业性，处方药和非处方药界限的模糊化扩大了患者的选择范围，同时也迫使生产商和经销商调整其行销、包装和患者教育策略，以适应更以零售为导向的环境。

最后，数位技术和分销创新正在重新定义病患接触点。远端医疗后续观察、远距药局服务和线上药局平台的兴起，正在改变患者接受治疗的地点和方式，为将持续照护和临床决策支援工具融入护理流程创造了机会。这些变化迫使现有企业重新定位其产品，增加对品质和合规性的投入，并设计能够反映全新患者体验和支付方优先事项的全通路策略。

评估近期消化性溃疡药物生产和分销关税变化如何推动供应链重组、近岸外包和一体化商业策略

近期影响医药原料和成品的关税措施和贸易政策调整，对整个产业的供应链经济和筹资策略带来了压力。某些进口药用原料药和辅料关税的提高，迫使生产商重新评估其采购基础，许多生产商都在权衡更高的到岸成本与供应商突然变更带来的营运风险。进口关税也会影响下游决策，例如契约製造合作伙伴的选择、库存布局以及多区域生产结构的可持续性。

从营运层面来看，关税正在加速近岸外包和在地化生产策略的采用，旨在降低跨境关税和运输波动带来的风险。这些转变通常需要对生产能力和品质系统进行资本投资，这可能会延长新产品上市的前置作业时间。对于依赖复杂全球供应链的公司而言，关税促使它们进行更完善的情境规划、对供应商生态系统进行压力测试，并加强围绕价格和供应连续性的合约保护。

在商业层面，关税加剧了成本压力，影响定价策略、与支付方的谈判以及销售管道的奖励。支付方和采购团队越来越关注总体拥有成本 (TCO)，其中包括物流成本、关税负担和监管合规费用。为此，製造商和经销商正在探索基本契约、批量采购协议和联合采购伙伴关係，以确保供货管道畅通并控制利润空间。这些调整凸显了采取综合性商业策略和供应链规划方法的必要性，以便预测和管理关税的影响，并在可能的情况下将其转化为竞争优势。

深度细分观点，将给药途径、销售管道、品牌类型、剂型、最终用户、通路和药物类别等因素与策略选择联繫起来。

细分市场层面的差异揭示了临床应用、商业策略和营运需求的重要区别，从而影响产品的开发、行销和交付方式。给药途径将市场划分为口服疗法（主要用于常规治疗和非处方药）和肠外疗法（主要用于急性住院治疗和有口服障碍的患者）。销售管道的不同也带来了不同的上市要求：非处方药优先考虑消费者通讯、包装和零售分销，而处方药则需要与处方医生合作、进行药品上市谈判以及开展药物监测项目。

品牌类型是策略差异化的新维度。品牌产品在差异化、临床证据和服务（例如病患支援计画）方面竞争，而学名药主要在成本竞争力、生产规模和分销效率方面竞争。剂型在营运和商业性都至关重要。胶囊、注射和片剂的生产流程、稳定性考量和患者接受度各不相同，这会影响产品生命週期规划。终端用户细分进一步决定了部署选择。居家医疗优先考虑便利性、简化的给药方案和病患教育工具；医院需要注射剂和静脉注射製剂以及强大的供应物流；而门诊诊所则需要在成本、依从性和给药便捷性之间取得平衡。

分销通路的特征同样重要。医院药局与住院病患的工作流程和临床管治紧密结合；线上药局优先考虑数位互动、合规性和末端物流；而零售药局则着重于货架陈列、促销活动和销售点咨询。最后，药物类别的特征也对临床和商业策略都至关重要。 H2受体拮抗剂和质子帮浦阻断剂在起效速度、效力和作用持续时间方面存在差异，而亚类和具体分子——例如西咪替丁、法莫替丁、尼扎替丁、雷尼替丁、埃索美拉Esomeprazole、兰索拉唑、奥美拉唑、泮托拉唑和Rabeprazole——则表现出不同的药代动力学特性和安全性。这些因素会影响处方指南、标籤策略和竞争定位。了解这些多层次细分市场的动态对于使研发重点、生产投资和市场推广工作与患者照护的实际情况和支付方的期望保持一致至关重要。

美洲、欧洲、中东和非洲以及亚太地区的区域监管、报销和供应链现状正在塑造差异化的市场进入和商业化策略。

区域趋势影响法规结构、报销标准和供应链结构，进而对策略规划产生重大影响。在美洲，监管机构和支付者强调循证处方处方集、成本控制机制以及公私合作采购模式，并评估已证实的临床价值和成本效益。这种环境鼓励製造商投资稳健的临床项目、真实世界证据的生成以及与支付方的合作策略，以在预算限制下平衡疗效。

欧洲、中东和非洲地区（EMEA）监管能力和报销政策的多样性要求企业制定复杂的打入市场策略。欧洲市场的特点是集中化或统一的核准流程和严格的卫生技术评估（HTA），而中东和北非（MENA）市场则呈现出采购模式多样化、临床基础设施差异以及各地监管文件要求不一的局面。製造商和经销商必须制定符合当地监管要求和采购习惯的授权策略、定价策略和供应链方案。

亚太地区呈现出高所得市场快速接受创新以及新兴经济体对高容量、成本敏感的需求并存的局面。该地区的政策制定者日益重视本地製造能力和药品自给自足，这正在影响外国製造商的市场进入策略和伙伴关係模式。在所有地区，数位化分销和远端医疗的普及正在改变患者的就医模式，因此需要製定区域性数位化互动和电子商务策略，以提升客户体验并维持良好的用药依从性。

决定製造商、学名药製造商、契约製造製造商、经销商和服务合作伙伴竞争优势的策略行动和能力。

为了保持竞争力，消化性溃疡治疗领域的相关人员必须在创新、品质和规模之间取得平衡。大型跨国製药公司往往投资于广泛的临床开发项目、完善的药物监测基础设施以及全球製造地，以支持品牌药和非专利的生产。这些公司优先考虑提高监管多样性、建立策略联盟以及应对复杂竞标环境的能力，尤其是在医院采购和国家处方集发挥关键作用的情况下。

学名药和专科药生产商专注于卓越的生产製造和成本优势，利用大规模生产和流程优化在价格和供应方面竞争。契约製造组织 (CMO) 和活性原料药(API) 供应商在维持供应连续性方面发挥核心作用，尤其是在企业采取多元化筹资策略以降低品质和地缘政治风险的情况下。经销商和连锁药局（包括线上平台）透过整合物流、进行病患教育倡议和使用数位化互动工具，在影响病患用药途径和用药依从性方面发挥着至关重要的作用。

在这个生态系统中，提供监管协助、品质保证审核和低温运输物流等服务供应商透过加快产品上市速度和减轻製造商的营运负担，创造了策略价值。商业机构与医院、专科诊所等临床相关人员之间的合作日益普遍，因为这些合作有助于产品进入处方集、收集真实世界证据，并进行上市后监测活动，进而提升产品定位和健保报销谈判的有效性。

提升供应链韧性、监管准备和全通路商业化能力，以维持消化性溃疡治疗领域竞争优势的实用策略

为了把握机会、降低风险，在不断变化的消化性溃疡药物市场中，产业领导者应优先考虑供应链韧性、监管灵活性和差异化的病人参与。加强供应商多元化策略，投资区域生产和双重采购安排，将有助于保障关键剂型的持续供应，同时降低贸易中断和关税波动带来的风险。此外，透过实施先进的供应商监控分析方法、加强批次级可追溯性以及主动评估污染风险，实现品质监控现代化，有助于维护产品完整性并符合监管要求。

在商业化过程中，必须针对非处方药和处方药市场的不同特点，设计客製化的全通路策略。这包括为居家患者提供数位支援和用药依从性指导，为医院和门诊医生提供有针对性的临床合作，以及优化零售和线上分销模式，以平衡便利性和依从性。价值验证活动应侧重于真实世界的疗效、安全性以及对整体医疗成本的影响，以符合支付方的优先事项并支持药物被纳入医保目录。

最后，经营团队应将监理情报分析和情境规划纳入策略决策。积极主动掌握监管趋势、及早与监管机构沟通以及投资于上市后监测系统，将有助于在出现安全讯号或政策变化时，迅速调整标籤和供应链。将业务永续营运、商业性精准性和监管前瞻性结合，不仅能帮助企业抵御市场衝击，还能帮助企业打造稳固的竞争优势。

检验済み知见を裏付けるため、一次専门家関与、二次规制・临床分析、サプライチェーンマッピングを组み合わせた厳密な混合研究手法フレームワークを采用

本分析采用多方法研究策略，结合一手访谈、二手文献综述以及结构化的供应链和监管分析，以确保研究结果的平衡性和检验。我们邀请了来自临床实践、药品生产、分销和采购领域的专家，收集他们对治疗管理、品质和生产挑战以及商业性需求的多元观点。此外，我们也利用了包括同侪审查的临床文献、监管建议、产业指导文件和公开文件在内的二手资料，以权威证据支持临床和政策的观察。

我们的供应链评估是基于供应商分布图、公开的海关和贸易数据检验以及物流路线分析，识别出通用的脆弱性因素和相应的缓解措施。我们的监管分析利用官方机构通讯、安全警报和指导文件，追踪不断变化的合规要求和报告义务。在整个研究过程中，我们透过对来自不同独立资讯来源的研究结果进行三角验证，以检验我们的结论并识别不确定性领域。

本调查方法的一个限制在于，它依赖公开的监管通讯和专家访谈，而这些资料可能无法涵盖独特的商业性安排或当前供应商的保密谈判。为了弥补这些局限性，本研究提供了透明的假设，并在适用情况下引用了监管观点，同时鼓励寻求详细专有资讯或客製化情境建模的机构进行额外的初步研究。

摘要强调，韧性、证据产生和以客户为中心的执行是消化性溃疡药物领域持续表现的基础。

消化性溃疡药物市场具有持续的临床需求、不断加强的监管以及不断演变的商业性模式等特点，所有这些都要求行业相关人员采取适应性策略。在临床方面，将有效的抑酸治疗与感染控制相结合仍然是重中之重，而安全性考量和患者偏好正在重塑长期用药方案。在营运方面，供应链的韧性和合规性是市场持续性和品牌声誉的核心决定因素。

商业性成功将越来越依赖以下能力：将产品系列与差异化的患者体验相匹配；向支付方证明产品的实际价值；以及实施能够抵御地缘政治和贸易衝击的灵活生产和采购模式。积极投资于品质保证、全通路病人参与和监管情报的机构，将更有能力将临床疗效转化为永续的市场进入和商业性成果。这些结论指向一个以韧性、实证和以客户为中心的执行为基础的策略蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 幽门螺旋桿菌菌株对抗生素抗药性的日益增强，推动了对新型根除疗法的需求。
  • 由于已开发市场广泛使用非专利PPI，价格竞争日益加剧
  • 开发缓释性药物递送系统以提高消化性溃疡治疗的依从性
  • 增加对细胞保护胜肽类似物作为下一代溃疡治疗药物的投资
  • 拓展基于患者基因谱和微生物基因组学的个人化治疗策略
  • 受消费者对草药疗法的偏好日益增长的推动，天然和植物来源的抗溃疡化合物的需求激增。
  • 关于长期使用质子帮浦抑制剂的监管建议正在重塑处方实践和患者管理指南。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按给药途径分類的消化性溃疡药物市场

  • 口服
  • 肠外

9. 消化性溃疡药物市场依销售管道划分

  • 非处方药
  • 处方药

第十章 按品牌类型分類的消化性溃疡药物市场

  • 品牌产品
  • 学名药

第十一章 按剂型分類的消化性溃疡治疗市场

  • 胶囊
  • 注射
  • 药片

第十二章 消化性溃疡药物市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 门诊部

第十三章 消化性溃疡药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

14. 消化性溃疡药物市场（依药物类别划分）

  • H2受体拮抗剂
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 质子帮浦阻断剂
    • Esomeprazole
    • 兰索拉唑
    • 奥美拉唑
    • 泮托拉唑
    • Rabeprazole

第十五章 各地区消化性溃疡药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 消化性溃疡药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国消化性溃疡药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AstraZeneca plc
    • Takeda Pharmaceutical Company Limited
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • Johnson & Johnson
    • Sanofi SA
    • GlaxoSmithKline plc
    • Bayer AG
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
Product Code: MRR-2A0283E25692

The Peptic Ulcer Drugs Market is projected to grow by USD 7.20 billion at a CAGR of 5.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.73 billion
Estimated Year [2025] USD 4.99 billion
Forecast Year [2032] USD 7.20 billion
CAGR (%) 5.38%

A concise orientation to current clinical, commercial, and supply-side dynamics shaping the peptic ulcer therapeutics environment and stakeholder decisions

Peptic ulcer therapeutics remain a cornerstone of gastroenterology practice, with a clinical focus that spans symptom control, mucosal healing, and complication prevention. Advances in acid suppression pharmacology and refined clinical pathways have reshaped how clinicians diagnose and manage peptic ulcer disease, shifting many care decisions from inpatient settings to ambulatory and home care environments. Patients and providers now benefit from a deeper understanding of Helicobacter pylori's role, the long-term implications of sustained acid suppression, and the need to balance efficacy with safety in chronic therapy.

Clinically, proton pump inhibitors have become the dominant modality for achieving profound and durable acid suppression, while H2 receptor antagonists continue to play a supporting role in selected scenarios and as short-term therapies. The therapeutic landscape has been influenced by regulatory actions, product recalls, and evolving OTC access models, which together affect prescriber behavior and patient self-management. Concurrently, the supply chain that brings these medicines from API production through finished-dose manufacturing to distribution and point-of-care has become more complex, influenced by global sourcing, regulatory harmonization, and evolving reimbursement practices.

This executive summary synthesizes current dynamics affecting the peptic ulcer drugs arena, emphasizing the interplay between clinical evidence, regulatory developments, commercialization channels, and operational realities. The aim is to provide decision-makers with a clear, actionable perspective that integrates therapeutic performance considerations with commercial and supply-side realities, supporting informed strategy development across product portfolios, distribution networks, and stakeholder engagement plans.

How scientific advances, regulatory scrutiny, and distribution innovation are driving a strategic reconfiguration of peptic ulcer therapeutics across care pathways

The therapeutic and commercial landscape for peptic ulcer drugs is undergoing transformative shifts driven by scientific advances, regulatory recalibration, and changes in patient access pathways. On the scientific front, improved mechanistic understanding of gastric acid physiology and mucosal protection has refined when and how aggressive acid suppression is deployed, prompting guideline revisions and more nuanced prescribing practices. At the same time, real-world safety data and pharmacovigilance findings have increased scrutiny of long-term therapy, leading to more deliberate deprescribing frameworks and shared decision-making tools that prioritize appropriate duration and monitoring.

Regulatory and quality challenges have also catalyzed change. Manufactured product integrity, API sourcing practices, and contamination incidents have led to tighter oversight and an emphasis on supplier transparency. These pressures are accelerating industry adoption of enhanced quality assurance measures and dual-sourcing strategies to protect continuity of supply. Commercially, the lines between prescription and over-the-counter access have blurred, expanding patient choice while forcing manufacturers and distributors to adapt marketing, packaging, and patient education efforts to a more retail-oriented context.

Lastly, digital and distribution innovations are redefining patient touchpoints. Telemedicine follow-ups, remote pharmacy services, and the growth of online pharmacy platforms have shifted where and how patients obtain therapies, creating opportunities to embed adherence support and clinical decision aids into the care continuum. Together, these shifts are compelling incumbent players to revisit product positioning, invest in quality and regulatory compliance, and design omnichannel strategies that reflect new patient journeys and payer priorities.

Assessing how recent tariff shifts are prompting supply chain redesign, nearshoring, and integrated commercial strategies across peptic ulcer drug production and distribution

Recent tariff actions and trade policy adjustments affecting pharmaceutical inputs and finished products are exerting pressure on supply chain economics and sourcing strategies across the industry. Increased duties on certain imported active pharmaceutical ingredients and excipients have prompted manufacturers to reassess their procurement footprints, with many evaluating the trade-offs between higher landed costs and the operational risks of rapid supplier substitution. Import tariffs can also influence downstream decisions about contract manufacturing partner selection, inventory positioning, and the viability of maintaining decentralized production across multiple jurisdictions.

From an operational viewpoint, tariffs have accelerated the adoption of nearshoring and regional manufacturing strategies aimed at mitigating exposure to cross-border duties and transport volatility. These shifts often require capital investment in manufacturing capacity and quality systems, and they can extend lead times for new product introductions. For companies that rely heavily on complex global supply chains, tariffs have encouraged the development of more robust scenario planning and stress-testing of supplier ecosystems, as well as stronger contractual protections around pricing and supply continuity.

On the commercial side, tariff-driven cost pressures are influencing pricing strategies, negotiations with payers, and channel incentives. Payers and procurement teams are increasingly attentive to total cost of ownership, which includes logistics, tariff burden, and regulatory compliance overhead. In response, manufacturers and distributors are exploring value-based contracting, bundled procurement arrangements, and collaborative sourcing partnerships to preserve access while managing margin compression. These adaptive measures underscore the need for integrated commercial and supply chain planning to ensure that tariff impacts are anticipated, managed, and, where possible, converted into competitive advantage.

Deep segmentation perspectives that connect administration routes, sales channels, brand types, dosage forms, end users, distribution channels, and drug classes to strategic choices

Segment-level distinctions reveal meaningful differences in clinical use, commercial strategy, and operational requirements that shape how products are developed, marketed, and delivered. Route of administration divides the landscape between oral therapies, which dominate routine management and OTC access, and parenteral options that are reserved for acute hospital care or patients unable to tolerate oral dosing. Sales channels create divergent go-to-market imperatives: over-the-counter availability prioritizes consumer-facing messaging, packaging, and retail distribution, while prescription drugs require prescriber engagement, formulary access negotiations, and pharmacovigilance programs.

Brand type introduces another axis of strategic differentiation. Branded products often compete on differentiation, clinical evidence, and service offerings such as patient support programs, whereas generics compete primarily on cost competitiveness, manufacturing scale, and distribution efficiency. Dosage form matters operationally and commercially; capsules, injections, and tablets each entail distinct manufacturing processes, stability considerations, and patient acceptance dynamics that influence product lifecycle planning. End-user segmentation further informs deployment choices, with home care favoring convenience, simplified regimens, and patient education tools, hospitals requiring injectable and IV-compatible formulations alongside robust supply logistics, and outpatient clinics balancing cost, adherence, and ease of administration.

Distribution channel nuances are equally consequential. Hospital pharmacies maintain tight integration with inpatient workflows and clinical governance, online pharmacies prioritize digital engagement, compliance, and last-mile logistics, and retail pharmacies emphasize shelf placement, promotional activity, and point-of-sale counseling. Finally, drug class characteristics underpin both clinical and commercial strategy. H2 receptor antagonists and proton pump inhibitors differ in onset, potency, and duration of effect, with subclasses and individual molecules such as cimetidine, famotidine, nizatidine, ranitidine, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole exhibiting distinct pharmacokinetic and safety profiles that inform prescribing guidance, labeling strategies, and competitor positioning. Understanding these layered segmentation dynamics is essential for aligning R&D priorities, manufacturing investments, and market access efforts with the realities of patient care and payer expectations.

Regional regulatory, reimbursement, and supply chain realities across the Americas, EMEA, and Asia-Pacific that shape differentiated market entry and commercialization approaches

Regional dynamics shape regulatory frameworks, reimbursement norms, and supply chain architectures in ways that materially affect strategic planning. In the Americas, regulatory authorities and payer systems emphasize evidence-based formularies, cost containment mechanisms, and a mix of public and private procurement approaches that reward demonstrated clinical value and cost-effectiveness. This environment incentivizes manufacturers to invest in robust clinical programs, real-world evidence generation, and payer engagement strategies that reconcile therapeutic benefits with budgetary constraints.

In Europe, the Middle East, and Africa, heterogeneity in regulatory capacity and reimbursement policies requires nuanced market entry strategies. European markets often feature centralized or harmonized approval pathways coupled with stringent HTA processes, while markets in the Middle East and Africa present a mosaic of procurement models, varying levels of clinical infrastructure, and differing demands for local regulatory documentation. Manufacturers and distributors must therefore tailor their licensing, pricing, and supply chain approaches to reflect local regulatory expectations and procurement behaviors.

The Asia-Pacific region presents a blend of rapid innovation adoption in some high-income markets and large-volume, cost-sensitive demand in emerging economies. Policymakers in the region have increasingly prioritized local manufacturing capacity and pharmaceutical self-sufficiency, which affects foreign manufacturers' market access strategies and partnership models. Across all regions, digital distribution and telehealth adoption are changing patient access patterns, necessitating region-specific digital engagement and e-commerce strategies to capture new customer journeys and preserve adherence outcomes.

Strategic behaviors and capabilities of manufacturers, generics producers, contract manufacturers, distributors, and service partners that determine competitive positioning

Industry players operating in the peptic ulcer therapeutics space must balance innovation, quality, and scale to remain competitive. Large multinational pharmaceutical firms tend to invest in broad clinical development programs, extensive pharmacovigilance infrastructure, and global manufacturing footprints that support both branded and generic portfolios. These firms prioritize regulatory diversification, strategic alliances, and the ability to navigate complex tendering environments, especially where hospital procurement and national formularies play a pivotal role.

Generic manufacturers and specialty producers focus on manufacturing excellence and cost leadership, leveraging high-volume production and process optimization to compete on price and availability. Contract manufacturing organizations and API suppliers are central to maintaining continuity of supply, particularly as firms pursue multi-sourcing strategies to mitigate quality and geopolitical risks. Distributors and pharmacy chains, including online platforms, play a critical role in shaping patient access and adherence through integrated logistics, patient education initiatives, and digital engagement tools.

Across this ecosystem, service providers that deliver regulatory support, quality assurance auditing, and cold chain logistics add strategic value by reducing time-to-market and lowering the operational burden on manufacturers. Partnerships between commercial organizations and clinical stakeholders-such as hospitals and specialty clinics-are increasingly common, as these collaborations facilitate formulary access, real-world evidence collection, and post-launch surveillance activities that reinforce product positioning and reimbursement negotiations.

Actionable strategies for strengthening supply resilience, regulatory readiness, and omnichannel commercialization to sustain competitive advantage in peptic ulcer therapeutics

Industry leaders should prioritize supply chain resilience, regulatory agility, and differentiated patient engagement to capture opportunities and mitigate risks in the evolving peptic ulcer therapeutics landscape. Strengthening supplier diversification strategies and investing in regional manufacturing or dual-sourcing arrangements will reduce vulnerability to trade disruptions and tariff volatility while supporting continuity of supply for critical dosage forms. Concurrently, companies should modernize quality oversight by implementing advanced analytics for supplier monitoring, enhanced lot-level traceability, and proactive contamination risk assessment to preserve product integrity and regulatory compliance.

On commercialization, organizations must design tailored omnichannel strategies that reflect the distinct dynamics of over-the-counter and prescription markets. This includes digital outreach and adherence support for home care patients, targeted clinical engagement for hospital and outpatient clinic prescribers, and optimized retail and online distribution models that address convenience and compliance. Value demonstration efforts should focus on real-world effectiveness, safety profiles, and total cost of care implications to align with payer priorities and to support favorable formulary positioning.

Finally, leaders should embed regulatory intelligence and scenario planning into strategic decision-making. Anticipatory regulatory mapping, early dialogue with authorities, and investment in post-market surveillance infrastructure will accelerate responsive labeling and supply adjustments when safety signals or policy shifts occur. By integrating operational resilience, commercial precision, and regulatory foresight, companies can not only withstand market disruptions but also create defensible competitive advantages.

A rigorous mixed-method research framework combining primary expert engagement, secondary regulatory and clinical analysis, and supply chain mapping to underpin validated insights

This analysis was developed using a multi-method research approach that combined primary interviews, secondary literature review, and structured supply chain and regulatory analysis to ensure balanced and validated insights. Subject-matter experts from clinical practice, pharmaceutical manufacturing, distribution, and procurement were consulted to capture diverse perspectives on therapeutic management, quality and manufacturing challenges, and commercial imperatives. Secondary sources included peer-reviewed clinical literature, regulatory advisories, industry guidance documents, and public filings to ground clinical and policy observations in authoritative evidence.

Supply chain assessments relied on supplier mapping, review of public customs and trade data, and analysis of logistics pathways to identify common vulnerabilities and mitigation strategies. Regulatory analysis drew on public agency communications, safety alerts, and guidance documents to track evolving compliance expectations and reporting obligations. Throughout the research process, findings were triangulated across independent sources to validate conclusions and to expose areas of uncertainty.

Limitations of the methodology include reliance on publicly available regulatory communications and expert interviews that may not capture proprietary commercial arrangements or the most recent confidential supplier negotiations. To mitigate these constraints, the study emphasizes transparent assumptions, cites regulatory positions where applicable, and recommends follow-up primary research for organizations seeking deep-dive, proprietary intelligence or custom scenario modeling.

Concluding synthesis emphasizing resilience, evidence generation, and customer-centric execution as pillars for sustained performance in peptic ulcer therapeutics

The peptic ulcer therapeutics arena is characterized by enduring clinical needs, ongoing regulatory vigilance, and evolving commercial modalities that together demand adaptive strategies from industry participants. Clinically, effective acid suppression and the integration of infection management remain priority imperatives, while safety considerations and patient preference are reshaping long-term use. Operationally, supply chain robustness and regulatory compliance are central determinants of market continuity and brand reputation.

Commercial success will increasingly depend on the ability to align product portfolios with differentiated patient journeys, to demonstrate real-world value to payers, and to deploy flexible manufacturing and sourcing models that withstand geopolitical and trade-related shocks. Organizations that proactively invest in quality assurance, omnichannel patient engagement, and regulatory intelligence will be best positioned to translate clinical efficacy into sustainable market access and commercial performance. These conclusions point toward a strategic roadmap built on resilience, evidence, and customer-centric execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing antibiotic resistance in H. pylori strains driving demand for novel eradication therapies
  • 5.2. Growing uptake of generic proton pump inhibitors leading to intensified price competition in developed markets
  • 5.3. Development of sustained-release drug delivery systems to enhance peptic ulcer treatment adherence
  • 5.4. Rising investment in cytoprotective peptide analogues as next generation ulcer healing agents
  • 5.5. Expansion of personalized therapy strategies based on patient genetic profiling and microbial genomics
  • 5.6. Surge in natural and plant-derived antiulcer compounds spurred by consumer preference for herbal remedies
  • 5.7. Regulatory advisories on long-term PPI use reshaping prescribing practices and patient management guidelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptic Ulcer Drugs Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Peptic Ulcer Drugs Market, by Sales Channel

  • 9.1. Over The Counter
  • 9.2. Prescription Drugs

10. Peptic Ulcer Drugs Market, by Brand Type

  • 10.1. Branded
  • 10.2. Generic

11. Peptic Ulcer Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Peptic Ulcer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Outpatient Clinics

13. Peptic Ulcer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Peptic Ulcer Drugs Market, by Drug Class

  • 14.1. H2 Receptor Antagonists
    • 14.1.1. Cimetidine
    • 14.1.2. Famotidine
    • 14.1.3. Nizatidine
    • 14.1.4. Ranitidine
  • 14.2. Proton Pump Inhibitors
    • 14.2.1. Esomeprazole
    • 14.2.2. Lansoprazole
    • 14.2.3. Omeprazole
    • 14.2.4. Pantoprazole
    • 14.2.5. Rabeprazole

15. Peptic Ulcer Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Peptic Ulcer Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Peptic Ulcer Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AstraZeneca plc
    • 18.3.2. Takeda Pharmaceutical Company Limited
    • 18.3.3. Eisai Co., Ltd.
    • 18.3.4. Pfizer Inc.
    • 18.3.5. Johnson & Johnson
    • 18.3.6. Sanofi S.A.
    • 18.3.7. GlaxoSmithKline plc
    • 18.3.8. Bayer AG
    • 18.3.9. Novartis AG
    • 18.3.10. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEPTIC ULCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC PEPTIC UL